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greater than 5 mg/IOO ml. A posItive result was obtained
in only 63% of patients with Bence-Jones proteinuria in
the present investigation. Morwver, other globulins which
were character;sed by means of electrophore,is ,and
immuno-elect~ophoresis, also sometimes led to a positive
screening result in the urine. Albustix (Ames Co., Miles
Laborat::Jries Inc., USA) cannot be used to detect Berice-
Jones protein, and salicylsulphonic acid, although sensi-
t'ive, lacks ~pecificity and give's a positive result for most
proteins in the urine.
It is noteworthy that in the present investigation one
quarter of patients with Eence-Jones proteinuria would
have been missed if adequately concentrated urine had
not been subjected to electrophoresis. The urine of any
person suspected of having multiple myelomatosis should
therefore be concentrated and submitted to electrophoresis.
If a band is found on electrophoresis, immuno-electro-
phoresis must then be done in order to characterise the
immunochemical specificity of the Bence-Jones band.
Professor Bothwell was in receipt of grants from the South
African Medical Research Council and the Atomic Energy
Board.
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Multiple Myeloma
PART 11. THE VALUE OF MELPHALAN






The results of the use of melphalan in 52 patients with
multiple myeloma have been analysed. The median survival
of the whole group of patients was 30 months, and of those
w:th renal insufficiency only 12,5 months. Bence-lones
proteinuria was also a poor prognostic finding,. but only
because of its association with renal failure. Patients with
Bence-Jones protcinur;a and normal renal function had a
median survival of 41 months. Responsiveness to therapy
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by criteria based on those of the Chronic Leukemial
Multip!e Myeloma Task Force could be assessed in 25
patients. Dramatic symptomatic relief occurred in all but
one of the responsive patients, but in only one-fifth of those
who did not respond to therapy.
S. Afr. Med. J., 48, 1026 (1974).
The value of melphalan in the treatment of multiple
myeloma has been demonstrated in a number of investi-
gations.'" Symptoms are usually ameliorated, and the
median survival, calculated from the time of diagnosis, is
24 months or more in patients treated with melphalan, and
less than a year when the patients are untreated.',3 This
article analyses the experience of the Haematology Clinic
of Johannesburg General Hospital in using melphalan
in the treatment of patients with multiple myeloma.
METHODS
The patient-population, the clinical, radiological, haema-
tological and biochemical abnormalities recorded at the
time of presentation, and the criteria used for establishing
the diagnosis of multiple myeloma have been described
in detail.'
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Fig. 1. Survival from time of diagnosis.
evidence of renal insufficiency. Twenty-one patients had
Bence-Jones proteinuria and no evidence of impairment
of renal function, and their median survival was 41 months.
The third factor considered was the patients' response to
therapy. Twenty-five patients fulfilled the conditions re-
quired for evaluation by the criteria we chose. The effects
of therapy on the levels of plasma paraprotein and urinary
Bence-Jones protein in an unresponsive and a responsive
patient are portrayed in Fig. 2. Ten patients (40%) quali-
fied as responders and 7 of them were alive at the time of
writing. It therefore appears that the median survival of
the responding group will be considerably longer than that
of the whole group of patients, although the exact value
cannot yet be determined (Fig. 1). Of the 10 patients who
responded to therapy, 9 had a dramatic improvement in
their symptoms, while only 3 of the 15 non-responders ex-
perienced symptomatic relief.
Sixteen of the 25 evaluable patients had an IgG para-
protein and 7 of these responded to treatment; and 6
patients had an 19A paraprotein, of whom one responded.
There were no differences between responders and non-
responders in the degree of bone marrow infiltration,
serum calcium concentration, serum uric-acid concen:ra-
tion or extent of skeletal involvement. Bone marrow de-
pression with peripheral cytopenia (white blood cell count
below 3 500/mm' and platelet count below 150 ODO/mm')
occurred at some time during treatment in 85% of patients
who responded to chemotherapy, but in only 33% of those
who did not.
Six of the evaluable patients had received the continuous
melphalan regimen and 19 the intermittent high·dose mel-
phalan-prednisone regimen. All 10 patients who responded
to therapy received the regimen of intermittent high-dose
chemotherapy. The mean time which elapsed before the
criteria of response were achieved, was 7 months. Five ad-
ditional patients who are at present being treated accord-
ing to this regimen show a steady fall in the 'M'-compo-
nent, but are not yet evaluable since they have not yet
reached 50% of the pre-treatment value.




Twenty-one of the 52 patients treated were known to be
alive at the time of writing. All patients lost to follow-up
were considered dead at the last date of observation. This
has been done to minimise errors in the calculation of
survival results. The median survival time calculated by the
life-table method was 30 months for the group as a whole
(Fig. I). The median survival for patients with IgG mye-
loma was 33 months. For patients with IgA myeloma it
was 31 months, and for those who had Hence-Jones
mye;oma it was 23 months.
The effects of several factors which have been shown to
influence survival in multiple myeloma were studied
separately. One of the best documented is the status of
renal function.' The median survival of all patients who
had renal failure at the time of diagnosis was 12,5 months
(Fig. 1). Thirteen of the 31 patients who are dead had had
evidence of renal insufficiency at the time of diagnosis.
Bence-Jones proteinuria, irrespective of the presence
or absence of a plasma paraprotein, was a poor prognostic
feature because of its association with renal impairment.
Thirty-four patients exhibited Bence-Jones proteinuria and
13 (38%) of them had renal impairment. Of the 18 patients
who had no Bence-Jones proteinuria, 5 (28%) showed
RESULTS
Treatment Regimens
One of two chemotherapeutic regimens was used in each
patient. Prior to 1970 melphalan was administered con-
tinuously. Seven days after an initial loading dose of
0,15 mg/kg, the patient was given between 1 and 3 mg of
melphalan daily. After 1970 the regimen suggested by
Alexanian and co-workers' was adopted. Each patient re-
ceived melphalan 0,25 mg/kg/day and prednisone 2,0
mg/kg/day for 4 days. The course was repeated at inter-
vals of approximately 6 weeks. In addition, patients re-
ceiving intermittent therapy were treated with allopurinol
(lOO mg every 8 hrs), beginning 48 hours before the start
of chemotherapy and continuing until 3 - 4 days after the
completion of the course. Patients were encouraged to take
fluids liberally at this time. Additional supportive therapy,
including blood transfusion, corticosteroid therapy for
hypercalcaemia and radiotherapy for painful bony lesions,
was given to all patients when necessary.
Response to therapy Was assessed by means of criteria
based upon those suggested by the Chronic Leukemia /
Multiple Myeloma Task Force of the National Cancer
Institute (USA).' A patient was considered to have re-
sponded to therapy if, after at least 3 months of therapy,
there was a decrease in the concentration of the 'M'-com-
ponent to less than half of the pre-treatment value, and to
less than 4,0 g/lOO ml; or a decrease in the level of
Bence-Jones proteinuria to less than half of the pre-
treatment value and to less than 0,5 g/day; and a return
towards normal in the haemoglobin, serum calcium and
serum albumin values where these were initially abnormal.
No patient with an increase in the size or number of
lytic bone lesions was considered responsive to therapy,
and a patient qualified as having responded only if the
criteria were sustained for 2 months or longer.
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Fig. 2. The effect of the intermittent high-dose melphalan-
prednisone therapeutic regimen on the 'M'-component con-
centration (solid line), and urinary Bence-Jones protein
concentration (dotted line), in a patient who failed to re-
spond to therapy (upper diagram), and one who re-
sponded to therapy (lower diagram). Courses of therapy
are indicated by vertical arrows. The patient who failed
to respond died 11 months after the commencement of
therapy, while the patient who responded remains well
and free of symptoms.
.'
lationship to the myeloma cell mass.' Alexanian and co-
workers' have demonstrated that patients whose tumours
are responsive to melphalan have a median survival that
is more than 2 years longer than those with unresponsive
tumours. The median survival of the latter group was in
fact no longer than that of untreated patients.' Forty per
cent of the evaluable patients in the present study fulfilled
the criteria of response to therapy. Other investigations
have reported response rates between 15% and 85%.,,5 In
the present study the median survival of responsive patients
will significantly exceed that of the group as a whole
(Fig. 1). Moreover, 90% of patients who responded to
therapy experienced a dramatic improvement in their
symptoms, while only 20% of non~responders obtained
symptomatic relief.
Although the numbers are too small for any definitive
conclusions to be drawn, the' present investigation sup-
ports the evidence of Alexanian and co-workers' regarding
the superiority of an intermittent high-dose melphalan-
prednisone regimen. The Acute Leukemia Group Band
the Eastern Co-operative Oncology Group have also re-
cently reported an improved response rate and a pro-
longation of survival in good-risk patients given a com-
bination of melphalan and prednisone.'· Although predni-
sone appears to be an important addition to the therapeutic
regimen for multiple myeloma, the difference in response
in our patients may be in part a reflection of inadequate
melphalan dosage used in patients receiving continuous
therapy. Significant leucopenia occurred in 85% of re-
sponders, but in only 33% of non-responders.
In our survey the average time taken for remission to
occur in responsive patients was 7 months, although sub-
jective improvement was usually rapid. The time taken to
achieve a remission appears to be longer in our patients
than it was in the group of patients reported by Alexanian
and his co-workers." Their experience indicated that more
than half the patients who respond to therapy achieve a
remission within 3 months. Johansson" has, however,
reported a better prognosis in patients whose immuno-


















Renal impairment is associated with a poor prognosis in
patients suffering from multiple myeloma.' Bence-Jones
proteinuria has also been reported to be associated with a
poor prognosis.' Our findings are, however, in keeping with
those of Galton; and indicate that survival is not impaired
if Bence-Jones proteinuria occurs in the absence of renal
failure. The poor prognosis of patients with Bence-Jones
myeloma also appears to be the result of renal insuffi-
ciency. In this study 5 of the 6 patients with the condition
had renal failure at the time of diagnosis.
The value of melphalan in prolonging the survival of
patients with multiple myeloma is apparent. The over-all
median survival of 30 months compares favourably with
that reported from other centres."'" The plasma 'M'·
component provides a means of measuring the response to
therapy, since it has been shown to bear a quantitative re-
We wish to thank the Director of the South African Institute
for Medical Research for facilities to carry out this study, and
the Medical Research Council and Atomic Energy Board for
financial support.
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